Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-3242 + Lenacapavir vs Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2026
- Primary completion
- Aug 2027
- Countries
- 4
01
Overview
A Phase 2 trial of GS-3242 in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Jun 2026; status: recruiting.
02
Drugs
GS-3242
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07645287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645287.